Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
批准号:
10244963
负责人:
Christopher I Li
金额:
$11.93万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2022-03-31
关键词:
AddressAdjuvantAfrican AmericanAgeAlaska NativeAnti-Inflammatory AgentsAspirinBody mass indexCancer ControlCancer EtiologyCessation of lifeClinicalColorectal CancerConsensusDataDevelopmentDiagnosisEnsureEthnic OriginEthnic groupEtiologyFamily history ofFormalinFrequenciesGene ExpressionGoalsHispanicsImmuneImmune responseIncidenceIndividualInterventionMalignant NeoplasmsMethodsMolecularMolecular ProfilingMutationNative AmericansNative-BornNested Case-Control StudyNot Hispanic or LatinoOutcomePIK3CA geneParaffin EmbeddingPatientsPopulationPrevention strategyPrimary PreventionPrognostic MarkerRNARaceResourcesRiskRisk FactorsSample SizeSamplingSecondary PreventionSelection for TreatmentsSmoking HistorySpecimenStromal CellsSurvival RateTimeTumor TissueUnderserved PopulationUnited StatesWorkbasecancer diagnosiscancer health disparitycancer preventionclinical decision-makingclinically actionablecolon cancer patientscolorectal cancer riskdesigndisparity reductionexperiencefeedinggenetic signatureimprovedimproved outcomemalignant breast neoplasmmedically underserved populationmolecular subtypesmortalitymulti-ethnicmulti-racialmultidimensional datanew therapeutic targetnovelnovel therapeuticsracial and ethnicracial and ethnic disparitiesracial differencesexsuccesstherapeutic targettranscriptome sequencingtranslational research programtumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary/abstract
While improvements in colorectal cancer (CRC) outcomes have been made over the past several decades,
pronounced disparities in CRC incidence and mortality rates by race/ethnicity persist in the United States. In
particular, CRC incidence and mortality rates among Alaska Native people (a particularly understudied
population) are 124% and 148% higher, respectively, compared to the overall national rates, and among
African Americans they are 21% and 39% higher, respectively. Our primary overarching goal is to reduce
disparities in CRC mortality, particularly those experienced by Alaska Natives and African Americans, through
improving approaches to identify patients with aggressive CRC at diagnosis and discovering novel potential
therapeutic targets relevant to these populations. To address this goal, we will conduct a nested case-control
study that utilizes highly clinically annotated tumor tissue specimens that are readily available from several
resources. Cases are CRC patients who died of CRC within 5 years of their diagnosis, and controls are
matched CRC patients who survived at least as long as the duration between diagnosis and death of the case
that they are matched to. We will include four groups of patients defined by race/ethnicity: Alaska Native
people, African Americans, Hispanics, and non-Hispanic whites with 70 cases of lethal CRC and 140 CRC
controls from each group (total n=840). To discover novel prognostic markers, we will perform RNAseq
analyses on RNA extracted from formalin-fixed paraffin embedded tumor material. The specific aims of this
proposal are as follows: 1. Assess differences in gene expression profiles across four racial/ethnic groups and
their relationships to selected CRC risk factors; 2. Discover predictors of CRC mortality across and within four
different racial/ethnic groups; and 3. Characterize and evaluate differences in the immune and stromal cell
populations in the tumor microenvironment associated with CRC mortality, overall and by race/ethnicity. This
study will generate novel multi-ethnic high-dimensional data that we envision feeding into larger studies with
translational goals focused on advancing novel intervention targets for primary and secondary prevention, and
developing clinically useful predictors of poor CRC outcomes that can be used to guide clinical decision
making. This study is designed to generate findings that will be of particular benefit to underserved populations
as this work is aimed directly at reducing long-standing racial/ethnic disparities in CRC outcomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
-
批准号:10466937
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Translational Research Program in Colorectal Cancer Disparities
-
批准号:10601404
-
项目类别:
-
资助金额:$70.31万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Translational Research Program in Colorectal Cancer Disparities
-
批准号:10244961
-
项目类别:
-
资助金额:$40.66万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
-
批准号:10044049
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Project 1: Discovery of novel tumor-tissue based predictors of lethal colorectal cancer by race/ethnicity
-
批准号:10601406
-
项目类别:
-
资助金额:$27.11万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Translational Research Program in Colorectal Cancer Disparities
-
批准号:10044047
-
项目类别:
-
资助金额:$120.4万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Translational Research Program in Colorectal Cancer Disparities
-
批准号:10466935
-
项目类别:
-
资助金额:$108.13万
-
财政年份:2020
-
负责人:Christopher I Li
-
依托单位:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
-
批准号:10642674
-
项目类别:
-
资助金额:$64.27万
-
财政年份:2018
-
负责人:Christopher I Li
-
依托单位:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
-
批准号:10380156
-
项目类别:
-
资助金额:$82.22万
-
财政年份:2018
-
负责人:Christopher I Li
-
依托单位:
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)
-
批准号:9898340
-
项目类别:
-
资助金额:$115.69万
-
财政年份:2018
-
负责人:Christopher I Li
-
依托单位:
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence
-
批准号:9317195
-
项目类别:
-
资助金额:$50.76万
-
财政年份:2017
-
负责人:Christopher I Li
-
依托单位:
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence
-
批准号:9666881
-
项目类别:
-
资助金额:$55.59万
-
财政年份:2017
-
负责人:Christopher I Li
-
依托单位:
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence
-
批准号:10362731
-
项目类别:
-
资助金额:$86.87万
-
财政年份:2017
-
负责人:Christopher I Li
-
依托单位:
Discovery and verification of novel biomarkers of colorectal cancer recurrence
-
批准号:8901802
-
项目类别:
-
资助金额:$108.41万
-
财政年份:2015
-
负责人:Christopher I Li
-
依托单位:
Discovery and verification of novel biomarkers of colorectal cancer recurrence
-
批准号:9263899
-
项目类别:
-
资助金额:$106.13万
-
财政年份:2015
-
负责人:Christopher I Li
-
依托单位:
Epidemiology of the four most frequent cancers following breast cancer
-
批准号:9331517
-
项目类别:
-
资助金额:$95.68万
-
财政年份:2014
-
负责人:Christopher I Li
-
依托单位:
Epidemiology of the four most frequent cancers following breast cancer
-
批准号:9119785
-
项目类别:
-
资助金额:$93.54万
-
财政年份:2014
-
负责人:Christopher I Li
-
依托单位:
Epidemiology of the four most frequent cancers following breast cancer
-
批准号:8830848
-
项目类别:
-
资助金额:$93.3万
-
财政年份:2014
-
负责人:Christopher I Li
-
依托单位:
Epidemiology of the four most frequent cancers following breast cancer
-
批准号:8930121
-
项目类别:
-
资助金额:$95.24万
-
财政年份:2014
-
负责人:Christopher I Li
-
依托单位:
Breast and Ovary Cancer Clinical Validation Center
-
批准号:8129566
-
项目类别:
-
资助金额:$79.81万
-
财政年份:2010
-
负责人:Christopher I Li
-
依托单位:
海外基金